Expert Ratings for Chinook Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided ratings for Chinook Therapeutics (NASDAQ:KDNY) within the last quarter, with 2 somewhat bullish and 8 indifferent. The average price target is $39.0, slightly below the current price of $39.18. The average price target has increased by 2.63% over the past month.
August 01, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts' ratings for Chinook Therapeutics are somewhat bullish, with a price target slightly below the current price.
The somewhat bullish ratings indicate that analysts see potential in the stock, but the price target being slightly below the current price suggests that they believe the stock is currently overvalued. This could lead to a neutral or slight downward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100